We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Cheek Swab Test Could Identify Biomarkers for Rheumatoid Arthritis

By LabMedica International staff writers
Posted on 14 Dec 2021
Print article
Illustration
Illustration

Cells from a cheek swab revealed biomarkers for rheumatoid arthritis that could lead to a way to diagnose and begin treatment before the disease develops, according to a new study.

In the study, researchers from Washington State University (Pullman, WA, USA) and Arthritis Northwest (Spokane, WA, USA) identified a set of epimutations in cells from women who had rheumatoid arthritis that were distinct from those without the joint-damaging autoimmune disease. Epimutations are molecular factors and processes around DNA that regulate genome activity, independent of DNA sequence. The discovery could advance treatment for rheumatoid arthritis. While current drug treatments have limited efficacy in many patients who have already developed the disease, some studies have shown that treatments begun in early stages of the disease can cause remission of symptoms. Having biomarkers could allow treatment to begin even earlier before the first signs of it start.

For the study, researchers collected buccal, or cheek, cells using a swab from two cohorts of women: a group of 26 Caucasian women and a group of 23 African-American women. In each group, about half of the women had rheumatoid arthritis with the other half serving as a control. Even though they are taken from the cheek, buccal cells allowed the researchers to conduct an epigenome-wide analysis. Translating literally as “above” the genome, an epigenome consists of chemical factors that can modify the genome and change its behavior. While not part of DNA itself, epimutations can still be passed down to subsequent generations.

In this study, the researchers found epimutations in areas called DNA methylation regions, among the women in both groups who had rheumatoid arthritis. The study was designed to see if there were differences between racial groups since African Americans have shown some signs of increased prevalence of rheumatoid arthritis. However, while some differences were noted, the researchers found a large overlap in epimutations among women with rheumatoid arthritis of both races, meaning the identified biomarkers hold a strong signal for the disease.

The findings add evidence that the disease is likely systemic, meaning it was found not just in immune system cells involved in rheumatoid arthritis development but in many different cells throughout the body. The research team also tested an immune-related monocyte cell type in blood samples from a portion of the women, but the buccal cells showed the epimutations as well, indicating that a relatively non-invasive diagnostic cheek swab test could be developed to screen for the disease.

“If we can identify these patients 10 years earlier before the disease develops, it opens up a whole arena of preventative medicine that we did not have access to before,” said Michael Skinner, a professor in WSU’s School of Biological Sciences.

Related Links:
Washington State University 
Arthritis Northwest 

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
Quantitative Immunoassay Analyzer
FIA8000
New
Blood Grouping Kit
ABO & RhD Blood Grouping Kit
New
Laboratory Centrifuge
M-BASIC

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.